Abstract | INTRODUCTION: METHODS: This article reviews unmet clinical needs in advanced MTC. The authors consider novel agents that have been studied in MTC, with a focus on the investigational agent cabozantinib. Up-to-date clinical data of cabozantinib in MTC are discussed. RESULTS: Recent clinical evaluation suggests that cabozantinib is the first agent to prolong progression-free survival in patients with progressive MTC. These findings indicate that cabozantinib may be an effective therapy in advanced MTC. No improvement in overall survival has been demonstrated but data are not mature. CONCLUSION:
Cabozantinib may be an effective treatment option for patients with advanced MTC and is worthy of further evaluation.
|
Authors | Madhavi Nagilla, Rebecca L Brown, Ezra E W Cohen |
Journal | Advances in therapy
(Adv Ther)
Vol. 29
Issue 11
Pg. 925-34
(Nov 2012)
ISSN: 1865-8652 [Electronic] United States |
PMID | 23104465
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
- Anilides
- Pyridines
- cabozantinib
- Protein-Tyrosine Kinases
|
Topics |
- Administration, Oral
- Adult
- Aged
- Anilides
(administration & dosage, adverse effects)
- Biopsy, Needle
- Carcinoma, Neuroendocrine
- Clinical Trials, Phase I as Topic
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Immunohistochemistry
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Invasiveness
(pathology)
- Neoplasm Staging
- Patient Selection
- Prognosis
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Pyridines
(administration & dosage, adverse effects)
- Survival Analysis
- Thyroid Neoplasms
(drug therapy, mortality, pathology)
- Treatment Outcome
|